Find us on:


Research Type
Reported as
Publication Type
Sort By
Total: 141
Low Dose Naltrexone: A Viable Alternative for Long Term Chronic Pain?
Research Type Human Reported as Case Report/Series/Restrospective Study Date March 15, 2019 Authors Victor Rivera; Joseph DeCicco; Samuel Espiritu Institution Naval Medical Center Portsmouth Disease Pain (chronic)
Over the past decade there has been significant advancement in understanding the multitude of ways naltrexone interacts with human physiology. The two main theories purported in literature are suppression of cytokine production by glial cells and transient blockade of the mu- opioid receptor. This case report highlights a chronic pain patient that sustained a wean from high dose opioid regimen utilizing low dose naltrexone. Her daily pain score, as calculated using the Defense and Veterans Pain ...
Sjogren's Syndrome: Clinical Benefits of Low-dose Naltrexone Therapy
Research Type Human Reported as Case Report/Series/Restrospective Study Date March 11, 2019 Authors Scott Zashin Institution University of Texas Southwest Medical Center Disease Sjogren’s
Sjogren’s Syndrome is a chronic autoimmune disorder that causes the inflammation of the lacrimal and salivary glands, resulting in dryness of the eyes and mouth. In addition, fatigue and musculoskeletal pain, often described as aching, is very common. Treatment directed toward alleviating the fatigue and pain associated with Sjogren’s is currently very limited. This report describes a case of a 47-year-old female with suspected Sjogren's based on long-standing dry eyes, dry mouth, joint pain...
Low dose naltrexone: Effects on medication in rheumatoid and seropositive arthritis. A nationwide register-based controlled quasi-experimental before-after study.
Research Type Human Reported as Case Report/Series/Restrospective Study Date February 14, 2019 Authors Guttorm Raknes, Lars Småbrekke Institution University Hospital of North Norway, Raknes Research, UiT - The Arctic University of Norway Disease Rheumatoid Arthritis, Seropositive Arthritis
In recent years, low dose naltrexone (LDN) has been used as an off-label therapy for several chronic diseases. Results from small laboratory and clinical studies indicate some beneficial effects of LDN in autoimmune diseases, but clinical research on LDN in rheumatic disease is limited. Using a pharmacoepidemiological approach, we wanted to test the hypothesis that starting LDN leads to reduced dispensing of medicines used in the treatment of rheumatic disease. We performed a controlled before-a...
Variable response to low-dose naltrexone in patients with Darier disease: a case series.
Research Type Human Reported as Case Report/Series/Restrospective Study Date February 03, 2019 Authors D. Boehmer, K. Eyerich, U. Darsow, T. Biedermann, A. Zink Institution Technical University of Munich Disease Darier Disease
BACKGROUND: Darier disease is a rare autosomal-dominant genodermatosis with a loss of function of a Ca2+ -ATPase pump (SERCA2-pump). Clinically, the disease is characterized by red-brown keratotic papules mainly in seborrheic areas and has only limited and unsatisfactory treatment options. Previously, low-dose naltrexone was described as a successful treatment option in Hailey-Hailey-disease, a genodermatosis with a genetic mutation coding for a similar loss of function of a Ca2+ -ATPase pump (h...
Treating chronic pain with low dose naltrexone and ultralow dose naltrexone: a review paper.
Research Type Human Reported as Review Date February 01, 2019 Authors Yoon Hang John Kim, Kirsten West Institution University of Kansas School of Medicine Disease Fibromyalgia
Naltrexone is an opioid receptor antagonist with FDA approval for treating opioid addiction since 1984. While typical dose for treating opioid addiction with naltrexone is between 50 mg to 150 mg, the use of low dose naltrexone (LDN) with doses ranging from 1.5 mg to 4.5 mg per day has been growing in popularity. The most common use of LDN has been treating autoimmune disorders; consequently, there have been clinical trials investigating the effectiveness of LDN for clinical conditions such as m...
Low-dose Naltrexone: An Alternative Treatment for Erythrodermic Psoriasis
Research Type Human Reported as Case Report/Series/Restrospective Study Date January 23, 2019 Authors E. P. Beltran Monasterio Institution Universidade Gama Filho Disease Erythmodermic Psoriasis, Psoriasis
This clinical case demonstrates the benefits of patient treatment with low-dose naltrexone(LDN) used in erythrodermic psoriasis. A patient with a confirmed history of psoriasis by histopathology was treated with 4.5 mg of LDN during six months follow-up after an erythrodermic psoriasis flare-up. The patient showed significant improvement in her flare-upand psoriasis remission after only three months of 4.5 mg of LDN on a daily basis. Low-dose-naltrexone (LDN) has proven to be a great ally in tre...
Serious adverse events reported in placebo randomised controlled trials of oral naltrexone: a systematic review and meta-analysis.
Research Type Human Reported as Review Date January 15, 2019 Authors Monica Bolton, Alex Hodkinson, Shivani Boda, Alan Mould, Maria Panagioti, Sarah Rhodes, Lisa Riste, and Harm van Marwijk Institution University of Manchester, University of Brighton
BACKGROUND: Naltrexone is an opioid antagonist used in many different conditions, both licensed and unlicensed. It is used at widely varying doses from 3 to 250 mg. The aim of this review was to extensively evaluate the safety of oral naltrexone by examining the risk of serious adverse events and adverse events in randomised controlled trials of naltrexone compared to placebo. METHODS: A systematic search of the Cochrane Central Register of Controlled Trials, MEDLINE, Embase, other databases an...
The Use of Low-Dose Naltrexone for Chronic Pain
Research Type Human Reported as Review Date January 01, 2019 Authors KM Bostick, AG McCarter, D Nykamp Institution Mercer University Disease Pain (chronic)
The use of low-dose naltrexone for the treatment of chronic pain is novel because it is a nonopioid alternative. Oral naltrexone in a dosage range from 1 mg to 4.5 mg is referred to as low-dose naltrexone. Low-dose naltrexone use is "off label" and has been used successfully to manage chronic pain, autoimmune disorders, and dermatologic conditions. Low-dose naltrexone could be a viable treatment option for chronic pain because other agents for chronic pain, such as nonsteroidal agents, have adve...
The Uses of Naltrexone in Dermatological Conditions
Research Type Human Reported as Review Date December 21, 2018 Authors B. Lee, D. Elston Institution Baylor College of Medicine; Medical University of South Carolina Disease Acantholytic skin disease, Alopecia, Darier Disease, Hailey-Hailey, Lichen Planopilaris, Pruritus, Psoriasis
BACKGROUND: Naltrexone in standard and reduced doses is efficacious in many inflammatory and acantholytic disorders. OBJECTIVE: We summarized current data of naltrexone relevant to dermatological practice. METHODS: An English language PubMed literature search was performed using the terms naltrexone, low-dose naltrexone, Hailey-Hailey, psoriasis, lichen planopilaris, alopecia, opioid, opioid receptor, treatment, dermatology, monitoring, side effect, skin, pruritus, cutaneous, acantholytic, and...
Intermittent blockade of OGFr and treatment of autoimmune disorders
Research Type Human Animal Reported as Review Date December 12, 2018 Authors IS Zagon, PJ McLaughlin PJ Institution Penn State University Disease AutoImmune (general), Crohn's Disease, Fibromyalgia, MS (Multiple Sclerosis)
This mini-review presents information on the intermittent blockade of the opioid growth factor (OGF)-OGF receptor (OGFr) axis by low-dose naltrexone (LDN), and the role of enkephalin (i.e. OGF) in autoimmune disorders, specifically multiple sclerosis, Crohn's, and fibromyalgia. Clinical reports on subjects taking LDN have documented reduced fatigue, few side-effects, and improved overall health. Preclinical studies on mice with experimental autoimmune encephalomyelitis (EAE), the animal model of...